| Trial ID: | L3248 |
| Source ID: | NCT00949663
|
| Associated Drug: |
Placebo
|
| Title: |
Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Placebo|DRUG: Glucose-dependent Insulinotropic Polypeptide (GIP)|DRUG: Xenin-25|DRUG: Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
|
| Outcome Measures: |
Primary: The effects of GIP, xenin-25, or a combination of GIP plus xenin-25 on insulin secretion and blood glucose levels, 3 years | Secondary: We will develop an assay to measure the normal fasting and postprandial concentrations of endogenous xenin-25 and determine whether they are altered in T2DM., 3 years
|
| Sponsor/Collaborators: |
Sponsor: Washington University School of Medicine | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
38
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-10
|
| Completion Date: |
2014-02
|
| Results First Posted: |
|
| Last Update Posted: |
2014-07-22
|
| Locations: |
Washington University School of Medicine, St. Louis, Missouri, 63110, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00949663
|
